Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zamerovimab (CTB011; SYN023), a composite of human monoclonal antibodies CTB011 and CTB012, targets distinct, non-overlapping epitopes on the rabies virus (RABV) glycoprotein, with CTB011 specifically binding to antigenic site III. This compound is applicable in rabies research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Zamerovimab (CTB011; SYN023), a composite of human monoclonal antibodies CTB011 and CTB012, targets distinct, non-overlapping epitopes on the rabies virus (RABV) glycoprotein, with CTB011 specifically binding to antigenic site III. This compound is applicable in rabies research [1]. |
In vitro | Zamerovimab (CTB011; SYN023) at concentrations ranging from 0.001 to 100 μg/mL for 4 hours induces dose-dependent cytotoxicity in BSR cells infected with CVS, facilitating viral clearance. This cytotoxic effect is also shown to correlate with the cell specificity for expressing the G protein, which are targeted by CTB011 [1]. |
In vivo | Zamerovimab (CTB011; SYN023), administered via intramuscular injection into the right gastrocnemius at doses ranging from 0.03 to 1.0 mg/kg for a single dose on day 35, was shown to increase the survival rate of Syrian hamsters infected with the rabies virus RABV BD06 in a dose-dependent manner. At doses of 0.03, 0.1, 0.3, and 1.0 mg/kg, the survival rates were 58%, 83%, 100%, and 100%, respectively [1]. |
Synonyms | SYN023, CTB011 |
Molecular Weight | N/A |
CAS No. | 2419087-87-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Zamerovimab 2419087-87-7 SYN023 CTB011 inhibitor inhibit